A biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable COVID-19 virus in the lungs of rhesus macaques, and protected their lungs from disease.
- Therapeutic administration of inhaled AR-701 substantially reduced and continued to suppress the viral load in the nasal sinus and oropharynx (upper respiratory tract region)
- Additional lab research also indicates both mAbs in the AR-701 cocktail are effective against the SARS-CoV-2 Omicron BA.1, BA.2, BA.4, BA.5 subvariants in vitro.
This research was conducted through a collective effort involving researchers at the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University (OHSU), the University of California at Davis, Vanderbilt University, the University of California at Irvine, and Aridis.
|